[225Ac]Ac-RYZ-SSA1

N/A

Report date: 2025/11/20 16:02:47

NME

Base Information

Drug Name[225Ac]Ac-RYZ-SSA1

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 agonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRayzeBio Inc

China Registration ClassN/A

Develop Information

Active CompaniesRayzeBio Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A